The Multiple Myeloma Channel is supported with funding from AbbVie (Platinum), Sanofi (Gold), Legend Biotech (Bronze), and through an educational grant from Alexion Pharma GmbH.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
IMS 2026 | Blood-based tools to reduce bone marrow biopsies in multiple myeloma
Luca Bertamini, MD, Erasmus MC, Rotterdam, Netherlands, discusses the potential of blood-based tools to reduce reliance on bone marrow biopsies for multiple myeloma monitoring. He highlights the potential of combining circulating tumor cells (CTCs), circulating DNA (ctDNA) and M-protein assessment, while noting that further research is needed. This interview took place at the 23rd International Myeloma Society (IMS) Annual Meeting in Glasgow, UK.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
